THE BALANCEhttps://thebalance.clinic/resources/medication/tapentadol/

Swiss roots. International expertise. Personal care, delivered with privacy and discretion.

THE BALANCE

Private admissions

Let’s talk about your next step.

Speak with our admissions team about treatment for you or someone you care about.

Privacy and discretion from the first conversation.

Your admissions team

Jil Moore
Jil MooreClient Relations Director
Cynthia Nakhle
Cynthia NakhleAdmissions Manager
Abdullah Boulad, Founder & CEO

Prefer to speak with our founder?

Abdullah Boulad · Swiss entrepreneur · Founder & CEO

Clinical resource

Tapentadol (Palexia): Uses, Risks, and Withdrawal

Learn about tapentadol and Palexia, including side effects, interactions, physical dependence, planned withdrawal, and when overdose needs emergency help.

Clinically reviewed byDr. Sarah Boss, MD
Stone residence with a swimming pool, lawn and palm trees

Quick Summary

  • Tapentadol is an opioid pain medicine; approved uses, age limits, and formulation instructions vary by country and product.
  • Alcohol and other sedating substances increase serious risks, while physical dependence alone is different from opioid use disorder.
  • Plan reductions with a clinician, and seek emergency help for slow breathing or inability to wake; use available naloxone as directed.

Tapentadol is an opioid pain medicine. It may be prescribed when the pain and treatment options justify using an opioid, but it can cause dependence, dangerous breathing suppression, overdose, and death. Take only the prescribed medicine and arrange regular reviews of its benefits and risks. [2]

What tapentadol does and when it is used

Tapentadol acts at mu-opioid receptors and reduces the reuptake of norepinephrine, both of which contribute to its pain-relieving effect. Palexia is one brand name. [1]

Immediate-release and extended-release products have different directions. In the United States, Nucynta tablets treat acute pain severe enough to require an opioid when alternatives are inadequate. Nucynta ER treats severe, persistent pain requiring extended treatment when alternatives, including immediate-release opioids, are inadequate. It is not an as-needed medicine. [2], [3]

Approved uses and age limits differ by country, formulation, and sometimes body weight. Some products have pediatric indications, while others are for adults. A child’s treatment must follow the exact local product information and an individual prescribing plan. [4], [15]

Ask what improvement in pain and everyday functioning is expected, which nonopioid treatments may help, and when treatment will be reviewed or ended. New or worsening pain needs reassessment, rather than an automatic dose increase. Opioids can sometimes increase sensitivity to pain. [7], [2]

An approved indication does not make a medicine the preferred treatment. Although US Nucynta ER labeling includes painful diabetic peripheral neuropathy, the American Academy of Neurology’s guideline advises against tapentadol and other opioids for this condition. Discuss alternatives with the prescriber; do not abruptly stop existing treatment. [3], [13]

Taking the prescribed product safely

Do not take extra doses, share the prescription, or change formulations yourself. Measure a prescribed liquid with the supplied oral syringe or another device recommended by the pharmacist, never a household spoon. Keep the medicine secure and out of children’s reach; ask a pharmacist about safe disposal. [5]

Palexia prolonged-release tablets and Nucynta ER must be swallowed whole, without dividing, chewing, or crushing. Altering them can release the medicine too quickly. Check the exact product instructions with a pharmacist instead of assuming every tapentadol tablet has the same handling rules. [4], [3]

Tell the prescriber about breathing problems or sleep apnea, bowel blockage, seizures or head injury, liver or kidney disease, and all other medicines. Some conditions rule out treatment or require a different plan. Do not convert between opioids using an internet calculation. [2]

Pregnancy and breastfeeding require prompt advice from the prescriber. Longer opioid use during pregnancy can cause newborn withdrawal, and use around delivery can suppress the baby’s breathing. The German Palexia retard leaflet says it must not be taken while breastfeeding. Plan any treatment change with the clinician rather than stopping suddenly yourself. [15], [9]

Side effects and important interactions

Nausea, vomiting, constipation, dizziness, and sleepiness can occur. Ask about persistent or troublesome effects and constipation prevention. Do not drive or operate machinery while drowsy or impaired. Sleepiness or constipation alone does not establish an addiction. [3], [8]

Seek emergency help for slow or shallow breathing, inability to wake, collapse, a seizure, or swelling of the face or throat with breathing difficulty. These are different from routine mild side effects. If breathing or consciousness is affected, do not wait for a routine appointment. [5]

Avoid alcohol. Benzodiazepines, sleeping medicines, other opioids, and other sedating drugs can intensify sedation and breathing suppression; gabapentin and pregabalin also increase this risk. Have the prescriber or pharmacist review all combinations. A half-life estimate cannot establish a safe drinking interval. [1]

Tapentadol can provoke seizures, with additional risk from medicines that lower the seizure threshold. Serotonin syndrome has been reported with serotonergic medicines, including some antidepressants. Agitation with fever, sweating, tremor, or muscle stiffness needs urgent assessment. Tell the prescriber about current or recent monoamine oxidase inhibitor use; this combination must be avoided under the product’s instructions. [6]

Dependence, opioid use disorder, and withdrawal

Physical dependence means the body has adapted and withdrawal may occur after a reduction or abrupt stop. Tolerance means the same amount has less effect over time. Neither alone establishes opioid use disorder. A broader pattern, such as difficulty controlling use, strong cravings, or continued use despite harm, warrants professional assessment. Tolerance and withdrawal alone are not counted as opioid use disorder criteria during appropriate medical treatment. [8]

After repeated use, stopping usually needs a gradual, individualized plan. Agree on follow-up, whom to contact, and how pain will continue to be treated. The pace may need adjustment if withdrawal becomes difficult. Serious adverse effects can require urgent medical changes; do not delay emergency help in order to follow a routine taper. [9]

Withdrawal may include restlessness, sweating, sleep difficulty, runny nose, aches, nausea, vomiting, or diarrhea. Timing and severity vary. Tell the clinician about symptoms during a reduction instead of assuming that every symptom is withdrawal. [5]

If opioid use disorder is identified, evidence-based treatment can include medication and continuing support. Withdrawal management alone is not a complete treatment for opioid use disorder and can increase later overdose risk without ongoing treatment. Seek assessment while still taking the medicine; pain care and addiction care should be coordinated. [10]

Suspected overdose: get help immediately

An opioid overdose can be fatal. Call the local emergency number immediately if the person is unresponsive or breathing slowly or shallowly. Give available naloxone according to its instructions and stay with the person until help arrives. Repeat administration may be needed. Naloxone is temporary, so emergency assessment is still necessary even if the person wakes up. [11]

For suspected poisoning, seek immediate medical advice even before symptoms appear. If unconscious but breathing normally, place the person on their side. If unresponsive and not breathing normally, follow the dispatcher’s CPR instructions. Do not induce vomiting or give anything to eat or drink. Keep the medicine packaging for responders. [12]

Questions

Frequently Asked Questions

Is Palexia the same as tapentadol?

Palexia contains tapentadol. The brand name alone does not identify the release formulation or instructions, so check the full product name and prescription. [1]

Is tapentadol the same as tramadol?

No. Both are opioid pain medicines, but they are different drugs. Do not substitute one for the other or assume one is automatically safer. A switch requires a prescriber’s assessment of the exact products and your circumstances. [14], [1]

Can I use tapentadol as a sleeping pill?

No. It is a pain medicine, and sleepiness is an adverse effect. Taking it to induce sleep can expose you to dangerous sedation and breathing problems. [5]

Can I stop tapentadol suddenly?

After repeated use, sudden stopping can cause withdrawal. Ask the prescriber for an individual reduction plan. Severe breathing problems, inability to wake, or other serious reactions need emergency help, not a self-managed taper. [9]

Does physical dependence mean I have an addiction?

No. Physical dependence can develop during prescribed treatment. Opioid use disorder involves a broader pattern that needs assessment, including impaired control or continued use despite harm. Discuss concerns openly with a clinician. [8]

Editorial evidence

Evidence & sources

Selected clinical guidelines, peer-reviewed research, and public-health sources used in this article.

01Grünenthal. Palexia retard: German Summary of Product Characteristics, November 2025.View source
02DailyMed. Nucynta immediate-release tablets: US prescribing information, December 2025.View source
03DailyMed. Nucynta ER: US prescribing information, December 2025.View source
View all 15 sourcesShow fewer sources
04AIFA. Palexia: Italian product information for tablets and oral solutions, made available May 22, 2026.View source
06MHRA. Tapentadol: seizure risk and reports of serotonin syndrome with other medicines.View source
07CDC. Guideline recommendations and principles for prescribing opioids for pain.View source
09NICE. NG215: prescribing and withdrawal management for medicines associated with dependence or withdrawal symptoms.View source
11FDA. Access to naloxone can save a life during an opioid overdose.View source
13American Academy of Neurology. Oral and topical treatment of painful diabetic polyneuropathy: guideline summary.View source
15Grünenthal. Palexia retard: German patient leaflet, November 2025.View source
What this includes
01

Clinical context

Clear information is framed around complex and co-occurring presentations.

02

Individual factors

Assessment remains essential because needs and risks differ from person to person.

03

Next steps

A confidential conversation can help clarify the most appropriate route forward.

Not sure where the situation fits?

Your admissions team

Jil Moore
Jil MooreClient Relations Director
Cynthia Nakhle
Cynthia NakhleAdmissions Manager

A confidential first conversation can help clarify the presentation and whether our setting is appropriate.

THE BALANCE
A PLACE TO BEGIN

Ask about our care